Open AccessJournal Article
Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Gasparini M,Rouesse J,van Oosterom A,T. Wagener,Riet Somers,Russel Ja,Voûte Pa,Bramwell,D. Thomas,Richard Sylvester +9 more
Reads0
Chats0
TLDR
CDDP adds to the limited number of chemotherapeutic agents with useful properties in osteogenic sarcoma, and CDDP-containing combination chemotherapy regimens should be actively investigated.Abstract:
The activity of cisplatin (CDDP) against advanced osteogenic sarcoma was evaluated in 37 of 50 patients registered by the members of the European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group between 1979 and 1982. All patients had measurable lung metastases. Thirty-one patients (84%) had received previous chemotherapy consisting mainly of high-dose methotrexate, doxorubicin, and vincristine. CDDP (100 mg/m2) was given as a 24-hour continuous infusion every 3 weeks for a minimum of two cycles, with appropriate fluids and diuretics. In the absence of impairment of the renal function and/or myelosuppression, the dose could be escalated by 20%. The overall response rate was 19% (seven responses among 37 patients), with one complete remission for 51 weeks and six partial remissions from 12 to 26 weeks. The median number of courses of CDDP administered was three, ranging from two to 11. Of 143 courses administered, only 18 (12%) had to be modified because of toxicity. In 16% of the patients some transient impairment of the renal function was observed. CDDP adds to the limited number of chemotherapeutic agents with useful properties in osteogenic sarcoma, and CDDP-containing combination chemotherapy regimens should be actively investigated.read more
Citations
More filters
Journal ArticleDOI
Biology and Therapeutic Advances for Pediatric Osteosarcoma
TL;DR: The authors review the state of the art management for patients with osteosarcoma in North America and Europe including the use of limb-salvage procedures and reconstruction as well as discuss the etiologic and biologic factors associated with tumor development.
Journal ArticleDOI
Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
Jakob K. Anninga,Hans Gelderblom,Marta Fiocco,Judith R. Kroep,Antoni H. M. Taminiau,Pancras C.W. Hogendoorn,R. Maarten Egeler +6 more
TL;DR: Meta-analysis in patients with localised high-grade osteosarcoma shows that 3-drug regimens, for example MAP are the most efficacious drug regimens and Salvage of poor responders by changing drugs, or intensifying treatment postoperatively has not proven to be useful.
Journal ArticleDOI
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
Neyssa Marina,Sigbjørn Smeland,Stefan S. Bielack,Mark L. Bernstein,Gordana Jovic,Mark Krailo,Jane Hook,Jane Hook,Carola A.S. Arndt,Henk van den Berg,Bernadette Brennan,Bénédicte Brichard,Kenneth L.B. Brown,Trude Butterfass-Bahloul,Gabriele Calaminus,Heike E. Daldrup-Link,Mikael Eriksson,Mark C. Gebhardt,Hans Gelderblom,Joachim Gerss,Robert E. Goldsby,Allen M. Goorin,Richard Gorlick,Holcombe E. Grier,Juliet Hale,Kirsten Sundby Hall,Jendrik Hardes,Douglas S. Hawkins,Knut Helmke,Pancras C.W. Hogendoorn,Michael S. Isakoff,Katherine A. Janeway,Heribert Jürgens,Leo Kager,Thomas Kühne,Ching C. Lau,Patrick J. Leavey,Stephen L. Lessnick,Leo Mascarenhas,Paul A. Meyers,Hubert Mottl,Michaela Nathrath,Zsuzsanna Papai,R. Lor Randall,Peter Reichardt,Marleen Renard,Akmal Safwat,Cindy L. Schwartz,Michael C. Stevens,Sandra J. Strauss,Lisa A. Teot,Mathias Werner,Matthew R. Sydes,Jeremy Whelan +53 more
TL;DR: The EURAMOS-1 results do not support the addition of ifosfamide and etoposide in patients with poorly responding osteosarcoma, and the primary outcome measure was event-free survival measured in the intention-to-treat population.
Journal ArticleDOI
The EORTC Soft Tissue and Bone Sarcoma Group
E. Donato Di Paola,O.S. Nielsen +1 more
TL;DR: In pretreated soft tissue sarcoma patients, Exatecan is well tolerated but does not achieve any objective responses, however, with respect to progression-free survival, exatecan did show some activity in leiomyosarcomas.
Journal ArticleDOI
The multidisciplinary management of osteosarcoma.
TL;DR: Treatment of osteosarcoma should be undertaken within the framework of large cooperative group clinical trials for children, adolescents, and adults and should be followed closely both for recurrence of disease and for development of late effects of the treatment of their cancer.